ScreenerHero

BHVN Biohaven Ltd.

NYSE · US · Healthcare · Biotechnology · biohaven.com
11.88USD-1.66%Mkt Cap: 1.79B $P/E: —

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.79B USD
Enterprise Value1.85B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-738.82M USD
Revenue/Share—
Last Price11.88 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees274
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.45
PEG—
EV/EBITDA-3.56
EV/Revenue—
P/S—
P/B149.14
EPS (TTM)-4.56
EPS (Forward)-1.87
52W Range
7.48040% of range18.57
52W High18.57 USD
52W Low7.480 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1418.85%
ROA-163.66%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-609.44M USD
CapEx (TTM)715.00K USD
FCF Margin—
FCF Yield-14.28%
Net Debt29.17M USD
Net Debt/EBITDA-0.06
Balance Sheet
Debt/Equity5.47
Current Ratio4.73
Quick Ratio4.28
Book Value/Sh0.08 USD
Cash/Share1.77 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.27 USD
Upside (mean)+79.0%
Target Range10.00 USD – 42.00 USD
10.00+79.0% to mean42.00
# Analysts15
Ownership
Shares Out.151.04M
Float116.57M
Insiders11.21%
Institutions95.72%
Short Interest
Short Ratio5.7d
Short % Float17.32%
Short % Out.13.54%
Shares Short20.45M
Short (prev mo.)17.82M
Technical
SMA 5014.07 (-15.6%)
SMA 20012.05 (-1.4%)
Beta3.20
S&P 52W Chg16.45%
Avg Vol (30d)3.34M
Avg Vol (10d)1.97M
Technical Indicators
RSI (14)36.3
MACD-0.4946
MACD Signal-0.3722
MACD Hist.-0.1224
BB Upper14.57 USD
BB Middle13.09 USD
BB Lower11.60 USD
BB Width22.70%
ATR (14)0.9017 USD
Vol Ratio (20d)0.73x